Nitric oxide paradox in asthma

Keller, Alexandre C.; Rodríguez, Dunia; Russo, Marco

doi:10.1590/s0074-02762005000900005

Cited by 21 publications

(14 citation statements)

References 34 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levels of exhaled nitric oxide are reported to be at a maximum midcycle when estrogen levels are highest. 32,33 Ethinylestradiol is a very potent estrogen, which might have direct inflammatory effects on the airways; we might also speculate whether such effects could increase with higher BMI to explain the observed interplay between OCP and BMI.…”

Section: Discussionmentioning

confidence: 99%

Oral contraception, body mass index, and asthma: A cross-sectional Nordic-Baltic population survey

Macsali

Real

Omenaas

et al. 2009

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Oral contraception, body mass index, and asthma: A cross-sectional Nordic-Baltic population survey

Macsali

Real

Omenaas

et al. 2009

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…Finally, it is still unclear whether NOS inhibition would be a good therapeutic target in parasitic infections. It is suggested that the detrimental effect of NOS is related to the L-arginine and NO concentrations, because NO at high concentration has a clear anti-inflammatory effect [139][140][141][142]. Thus, activation of NO could be a potential therapeutic strategy to suppress parasitic infections [143][144][145].…”

Section: Conclusive Remarksmentioning

confidence: 99%

Involvement of nitric oxide and its up/down stream molecules in the immunity against parasitic infections

Nahrevanian

2009

Braz J Infect Dis

View full text Add to dashboard Cite

Nitric oxide (NO) is a potent mediator with diverse roles in regulating cellular functions and signaling pathways. The NO synthase (NOS) enzyme family consists of three major isoforms, which convey variety of messages between cells, including signals for vasorelaxation, neurotransmission and cytotoxicity. This family of enzymes are generally classified as neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). Increased levels of NO are induced from iNOS during infection; while eNOS and nNOS may be produced at the baseline in normal conditions. An association of some key cytokines appears to be essential for NOS gene regulation in the immunity of infections. Accumulating evidence indicates that parasitic diseases are commonly associated with elevated production of NO. NO plays a role in the immunoregulation and it is implicated in the host non-specific defence in a variety of infections. Nevertheless, the functional role of NO and NOS isoforms in the immune responses of host against the majority of parasites is still highly controversial. In the present review, the role of parasitic infections will be discussed in the controversy related to the NO production and iNOS gene expression in different parasites and a variety of experimental models.

show abstract

“…In the present study, IL-13 production was diminished by GRRK treatment. IL-13 is involved in mucus hypersecretion and subepithelial fibrosis [33] and overexpression of IL-13 has been reported in asthma patients [34]. Similar studies reported that intratracheal IL-13 delivery successfully induces lung eosinophilia and airway hyperresponsiveness in mice [35][36][37][38][39].…”

Section: Discussionmentioning

confidence: 65%

Preventive and curative glycoside kaempferol treatments attenuate the TH2-driven allergic airway disease

Medeiros

Faustino

Borduchi

et al. 2009

International Immunopharmacology

View full text Add to dashboard Cite

Asthma is a chronic respiratory disease characterized by airway inflammation and airway hyperresponsiveness (AHR). One strategy to treat allergic diseases is the development of new drugs. Flavonoids are compounds derived from plants and are known to have antiallergic, anti-inflammatory, and antioxidant properties. To investigate whether the flavonoid kaempferol glycoside 3-O-[beta-d-glycopiranosil-(1-->6)-alpha-l-ramnopiranosil]-7-O-alpha-l-ramnopiranosil-kaempferol (GRRK) would be capable of modulating allergic airway disease (AAD) either as a preventive (GRRK P) or curative (GRRK C) treatment in an experimental model of asthma. At weekly intervals, BALB/c mice were subcutaneously (sc) sensitized twice with ovalbumin (OVA)/alum and challenged twice with OVA administered intranasally. To evaluate any preventive effect, GRRK was administered 1h (hour) before each OVA-sensitization and challenge, while to analyze the curative effect, mice were first sensitized with OVA, followed by GRRK given at day 18 through 21. The onset of AAD was evaluated 24h after the last OVA challenge. Both treatments resulted in a dose-dependent reduction in total leukocyte and eosinophil counts in the bronchoalveolar lavage fluid (BAL). GRRK also decreased CD4(+), B220(+), MHC class II and CD40 molecule expressions in BAL cells. Histology and lung mechanic showed that GRRK suppressed mucus production and ameliorated the AHR induced by OVA challenge. Furthermore, GRRK impaired Th2 cytokine production (IL-5 and IL-13) and did not induce a Th1 pattern of inflammation. These findings demonstrate that GRRK treatment before or after established allergic lung disease down-regulates key asthmatic features. Therefore, GRRK has a potential clinical use for the treatment of allergic asthma.

show abstract

Nitric oxide paradox in asthma

Abstract: Asthma results from allergen-driven intrapulmonary

Cited by 21 publications

References 34 publications

Oral contraception, body mass index, and asthma: A cross-sectional Nordic-Baltic population survey

Oral contraception, body mass index, and asthma: A cross-sectional Nordic-Baltic population survey

Involvement of nitric oxide and its up/down stream molecules in the immunity against parasitic infections

Preventive and curative glycoside kaempferol treatments attenuate the TH2-driven allergic airway disease

Contact Info

Product

Resources

About